Abstract
Background Pegfilgrastim is a G-CSF that can be administered in a single dose 24 h after each cycle of chemotherapy. Case 59 years-old man with a stage III-B peripheral T lymphoma with CD4 expression. Dose-dense chemotherapy was started with CHOP-14 combined with pegfilgrastim as primary prophylaxis. An error in the dispensing system meant that the patient received pegfilgrastim for 4 consecutive days. He remained under observation in hospital. During the 3 days after the last dose of pegfilgrastim, the patient remained stable, with no remarkable symptoms or associated laboratory abnormalities, and was discharged. Conclusion The case we describe and the available literature lead us to suggest close monitoring as the main measure to be adopted when treating a patient for pegfilgrastim overdose.
This is a preview of subscription content, log in via an institution to check access.
References
Aapro M, Crawford J, Kamioner D. Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer. 2010;18:529–41.
Neulasta® (pegfilgrastim) Summary of Product Characteristics (Spanish). Accessed Aug 27, 2010. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000420/WC500025945.pdf.
Dufour C, Cappelli B, Calvillo M, Fioredda F, Tonelli R. Similar favorable outcome of pegfilgrastim overdose in patients with different age and underlying disease. Haematologica. 2010;95:684–5.
Kaidar-Person O, Moskovitz M, Charas T, Alsharbati W, Haim N. Pegfilgrastim overdose: case report and review of the literature. Med Oncol. 2011;28(Suppl 1):697–8. Epub 2010 Nov 24.
Donadieu J, Beupain B, Rety-Jacob F, Nove-Josserand R. Respiratory distress and sudden death of a patient with GSDIb chronic neutropenia: possible role of pegfilgrastim. Haematologica. 2009;94:1175–7.
Wolff AC, Jones RJ, Davidson NE, Jeter SC, Stearns V. Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support. J Clin Oncol. 2006;24:2392–4.
Conflicts of interest
The authors have no conflict of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Riu, G., Estefanell, A., Nomdedeu, M. et al. Overdose of pegfilgrastim: case report. Int J Clin Pharm 34, 690–692 (2012). https://doi.org/10.1007/s11096-012-9653-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-012-9653-z